Dipti Mehta has worked as a Senior Application Scientist at Revvity since 2022. Her research in DNA and protein assay development with LabChip GX Touch technology has generated new commercial assays.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the launch of Revvity Transcribe AI, an innovative optical character recognition (OCR) service designed to convert ...

As nucleic acid–based therapeutics evolve and mature, so too must the analytical tools that are designed to characterize them. New microfluidic capillary electrophoresis (CE) methods that are designed ...

Revvity, Inc. is set to boldly unveil its new branding while showcasing more than 40 products from its life sciences and diagnostics portfolio at SLAS2024 to be held in Boston from February 3-7 in ...

Revvity reported revenues of $698.9 million, up 2.1% year on year. This print was in line with analysts’ expectations, and overall, it was a satisfactory quarter for the company with a decent beat of ...

Revvity emerged from the life sciences and diagnostics business of PerkinElmer (MA, USA) in May 2023 when the company divested its food, applied and enterprise services businesses. These businesses ...

WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)--Revvity, Inc. and Element Biosciences, Inc., a developer of the AVITI™ System, an innovative and emerging genomic sequencing platform, today announced a ...

Revvity, Inc. ( (RVTY)) has released its Q3 earnings. Here is a breakdown of the information Revvity, Inc. presented to its investors. Take advantage of TipRanks Premium at 50% off! Unlock powerful ...